Latest (66) Full Text Articles (1570) Focus on Esophagitis Article Summary

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
Gastroenterology, 01/24/2014  Clinical Article

Zeuzem S, et al. – The authors performed a phase IIb, randomized, double–blind, placebo–controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon–α2a (PegIFN), and ribavirin (RBV) in patients with hepatitis C virus (HCV) genotype–1 infection previously treated with PegIFN and RBV. In treatment–experienced patients, 12, 24, or 48 weeks simeprevir (100 mg or 150 mg once daily) in combination with 48 weeks PegIFN and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, and RBV and was generally well tolerated.

Methods

  • The authors analyzed data from patients who did not respond (null response), had a partial response, or relapsed after treatment with PegIFN and RBV, randomly assigned to receive simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks (n = 396), or placebo plus PegIFN and RBV for 48 weeks (n = 66).
  • All patients were followed for 24 weeks after planned end of treatment; the primary end point was the proportion of patients with sustained virologic response (SVR; undetectable HCV RNA) at that time point.

Results

  • Overall, rates of SVR at 24 weeks were significantly higher in the groups given simeprevir than those given placebo (61%-80% vs 23%; P < .001), regardless of prior response to PegIFN and RBV (simeprevir vs placebo: prior null response, 38%-59% vs 19%; prior partial response, 48%-86% vs 9%; prior relapse, 77%-89% vs 37%).
  • All groups had comparable numbers of adverse events; these led to discontinuation of simeprevir or placebo and/or PegIFN and RBV in 8.8% of patients given simeprevir and 4.5% of those given placebo.

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from PDR - powered by MDLinx

Most Popular Gastroenterology Articles

Last month's top read Top Articles of 2014

1 Urine test for early stage pancreatic cancer now possible after biomarker discovery Queen Mary University of London News, August 11, 2015

2 UCLA scientists discover experimental therapy for chronic inflammatory bowel disease, colon cancer UCLA Health System, July 31, 2015

3 Revealed Helicobacter pylori's secret weapon University of Nottingham News, August 17, 2015

4 Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity-score landmark analysis Journal of Hepatology, July 30, 2015    Clinical Article

5 Bacteria that prevents type 1 diabetes Inserm (Institut national de la santé et de la recherche médicale), August 10, 2015

6 Red grape chemical may help prevent bowel cancer but less is more University of Leicester News, July 31, 2015

7 Systematic review with meta-analysis: Faecal diversion for management of perianal Crohn's disease Alimentary Pharmacology and Therapeutics, August 13, 2015    Evidence Based Medicine    Review Article

8 “And then you start to loose it because you think about Nutella”: The significance of food for people with inflammatory bowel disease - a qualitative study Full Text BMC Gastroenterology, July 30, 2015    Free full text    Clinical Article

9 Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study Alimentary Pharmacology and Therapeutics, August 17, 2015    Clinical Article

10 FDA approves non-surgical temporary balloon device to treat obesity Full Text FDA Press Announcements, July 29, 2015    Free full text

11 Newly discovered cells regenerate liver tissue without forming tumors UC San Diego Health System, August 14, 2015

12 Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease Alimentary Pharmacology and Therapeutics, August 20, 2015    Clinical Article

13 The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity European Journal of Internal Medicine , August 4, 2015    Clinical Article

14 Wireless microcamera clusters broaden laparoscopic imaging University of Wisconsin-Madison News, August 25, 2015

15 Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease Clinical Pharmacokinetics, August 11, 2015    Review Article

16 Gastro-esophageal acid reflux control 5 years after anti-reflux surgery, compared with long-term esomeprazole therapy Clinical Gastroenterology and Hepatology , August 4, 2015    Clinical Article

17 Risk factors for 30-day readmission following colorectal surgery: A systematic review Journal of Surgical Research, July 7, 2015    Evidence Based Medicine    Review Article

18 Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining therapeutic goals for treat-to-target The American Journal of Gastroenterology, August 28, 2015    Review Article

19 Clinical characteristics of Helicobacter pylori-negative drug-negative peptic ulcer bleeding Full Text World Journal of Gastroenterology, July 30, 2015    Free full text    Clinical Article

20 Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study Alimentary Pharmacology and Therapeutics, August 7, 2015    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Other Topics in Gastroenterology

Register now to view all our site's content (FREE)!

View Samples and Register